In the CAVALLI phase, 2 studies of venetoclax plus R-CHOP as first-line treatment of DLBCL, the 2-year PFS and OS of venetoclax plus R-CHOP were higher than R-CHOP alone, observed in all DLBCL patients (2-year PFS: 80% vs 67%; 2-year OS: 86% vs 81%), as well as patients with BCL2 + DLBCLs and DELs. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.